Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.

Authors :: Kallieri M
Papaioannou AI
Zervas E
Fouka E
Porpodis K
Hadji Mitrova M
Tzortzaki E
Makris M
Ntakoula M
Lyberopoulos P
Dimakou K
Koukidou S
Ampelioti S
Papaporfyriou A
Katsoulis K
Kipourou M
Rovina N
Antoniou K
Vittorakis S
Bakakos P
Steiropoulos P
Markopoulou K
Avarlis P
Papanikolaou ΙC
Markatos M
Gaki E
Samitas K
Glynos K
Papiris SA
Papakosta D
Tzanakis N
Gaga M
Kostikas K
Loukides S
Source :: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2024 Apr; Vol. 54 (4), pp. 286-290. Date of Electronic Publication: 2023 Dec 12.
Publication Year :: 2024

Subjects :: Humans
Omalizumab therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Asthma drug therapy
Anti-Asthmatic Agents therapeutic use

Language :: English
ISSN :: 1365-2222
Volume :: 54
Issue :: 4
Database :: MEDLINE
Journal :: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Publication Type :: Editorial & Opinion
Accession number :: 38084474
Full Text :: https://doi.org/10.1111/cea.14436

Full Text Access

Tools